CA2136303A1 - Improved antiandrogens - Google Patents

Improved antiandrogens

Info

Publication number
CA2136303A1
CA2136303A1 CA002136303A CA2136303A CA2136303A1 CA 2136303 A1 CA2136303 A1 CA 2136303A1 CA 002136303 A CA002136303 A CA 002136303A CA 2136303 A CA2136303 A CA 2136303A CA 2136303 A1 CA2136303 A1 CA 2136303A1
Authority
CA
Canada
Prior art keywords
alpha
ring
separated
intervening atoms
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002136303A
Other languages
English (en)
French (fr)
Inventor
Fernand Labrie
Yves M. Merand
Shankar M. Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endorecherche Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2136303A1 publication Critical patent/CA2136303A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J73/00—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms
    • C07J73/001—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom
    • C07J73/005—Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by substitution of one or two carbon atoms by hetero atoms by one hetero atom by nitrogen as hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/0037—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being a saturated hydrocarbon group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0044—Alkenyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C07J1/004—Androstane derivatives substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
    • C07J1/0048—Alkynyl derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J21/005—Ketals
    • C07J21/006—Ketals at position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
CA002136303A 1993-05-17 1993-05-20 Improved antiandrogens Abandoned CA2136303A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6061293A 1993-05-17 1993-05-17
US08/060,612 1993-05-17

Publications (1)

Publication Number Publication Date
CA2136303A1 true CA2136303A1 (en) 1994-11-24

Family

ID=22030624

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002136303A Abandoned CA2136303A1 (en) 1993-05-17 1993-05-20 Improved antiandrogens

Country Status (14)

Country Link
EP (1) EP0650495B1 (OSRAM)
JP (1) JP2741286B2 (OSRAM)
KR (1) KR100241228B1 (OSRAM)
AT (1) ATE197458T1 (OSRAM)
CA (1) CA2136303A1 (OSRAM)
CZ (2) CZ285893B6 (OSRAM)
DE (1) DE69329649D1 (OSRAM)
FI (1) FI945458L (OSRAM)
HU (1) HUT69408A (OSRAM)
PL (1) PL307333A1 (OSRAM)
RU (1) RU2141966C1 (OSRAM)
SK (1) SK139194A3 (OSRAM)
TW (1) TW259791B (OSRAM)
WO (1) WO1994026767A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5879711A (en) * 1997-11-07 1999-03-09 Sequeira; Joel A. Stable antiandrogenic gel composition
BR9908592A (pt) 1998-03-11 2001-04-24 Endorech Inc Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
WO2002089802A2 (en) 2001-05-08 2002-11-14 Schering Corporation Use of neurokinin receptor antagonists to treat androgen-dependent diseases
KR100991616B1 (ko) 2001-09-06 2010-11-04 쉐링 코포레이션 안드로겐 의존성 질환 치료용 17β-하이드록시스테로이드데하이드로게나제 유형 3 억제제
PE20030705A1 (es) 2001-10-17 2003-08-21 Schering Corp Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes
AU2003219656B2 (en) * 2002-01-15 2007-05-17 Merck Sharp & Dohme Corp. 17-hydroxy-4-aza-androstan-3-ones as androgen receptor modulators
US7074795B2 (en) 2002-11-18 2006-07-11 Schering Corporation 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
CA2509758A1 (en) 2002-12-17 2004-07-22 Schering Corporation 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1081494A (en) * 1965-09-14 1967-08-31 British Drug Houses Ltd 17ª‡-(alka-1',3'-diynyl)-steroids
US3875188A (en) * 1968-04-10 1975-04-01 Eugene E Galantay 17-Beta-alpha-lower alkyl allene-substituted steroids
JPS5513273A (en) * 1978-07-13 1980-01-30 Kanebo Ltd Readily absorbable thiazolidine prodrug of anti- inflammatory corticosteroid and its drug composition
FR2430952A1 (fr) * 1978-07-13 1980-02-08 Roussel Uclaf Nouveaux derives acetyleniques de l'androst 4-ene, leur procede de preparation et leur application comme medicament
WO1991000732A1 (en) * 1989-07-07 1991-01-24 Endorecherche Inc. Androgen derivatives for use in the inhibition of sex steroid activity

Also Published As

Publication number Publication date
DE69329649D1 (de) 2000-12-14
RU2141966C1 (ru) 1999-11-27
HUT69408A (en) 1995-09-28
ATE197458T1 (de) 2000-11-11
EP0650495B1 (en) 2000-11-08
JP2741286B2 (ja) 1998-04-15
SK139194A3 (en) 1995-07-11
WO1994026767A1 (en) 1994-11-24
CZ282494A3 (en) 1995-12-13
CZ285893B6 (cs) 1999-11-17
RU94046463A (ru) 1997-02-27
EP0650495A1 (en) 1995-05-03
KR100241228B1 (ko) 2000-02-01
JPH08510988A (ja) 1996-11-19
PL307333A1 (en) 1995-05-15
FI945458A0 (fi) 1994-11-21
FI945458A7 (fi) 1995-01-16
TW259791B (OSRAM) 1995-10-11
FI945458L (fi) 1995-01-16
CZ287991B6 (cs) 2001-03-14

Similar Documents

Publication Publication Date Title
US5494914A (en) Inhibitors for testosterone 5α-reductase activity
DE3871965T2 (de) Steroid-5-alpha-reduktase-inhibitoren.
DE69314769T2 (de) 17-beta-substituierte 4-aza-5-alpha-androstan-3-on derivate
DE69313114T2 (de) NEUE DELTA-17 UND DELTA-20 UNGESÄTIGTE UND GESATIGTE 17--g(b)-SUBSTITUIERTE-4-AZA-5-g(a)-ANDROSTAN-3-ON VERBINDUNGEN ALS INHIBITOREN VON 5-ALPHA-REDUCTASE
JP3337689B2 (ja) １５−置換４−アザステロイド
HUT71484A (en) Process for producing of 7beta-substituted-4-aza-5alpha-cholestan-ones as 5-alpha-reductase inhibitors and pharmaceuticals compositions containing them
JP2000256390A (ja) 性ステロイド活性を抑制するために用いるエストロゲン核誘導体の医薬組成物
CA2136303A1 (en) Improved antiandrogens
NZ236966A (en) 7-substituted androstan-3,17-dione derivatives and medicaments
WO2000047603A9 (de) 16-hydroxyestratriene als selektiv wirksame estrogene
EP0756481B1 (en) 17$g(b)-ARYL-4-AZA-STEROID DERIVATIVES
US6015806A (en) Antiandrogens
JPH0246566B2 (OSRAM)
EP0059146B1 (fr) Nouveaux médicaments dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one, produits dérivés de la 3-hydroxy dodécahydro benz (e) inden-7-one et leur procédé de préparation
EP0721462A1 (en) 4-azasteroids with side-chain fluoroketones
AU718358B2 (en) Inhibitors of testosterone 5-alpha reductase activity
US3547911A (en) Synthesis of antheridiol and its derivatives
MC1121A1 (fr) Nouveaux d-homosteroides

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued